NEW YORK, September 25, 2020 - The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Nextcure, Inc. (NASDAQ: NXTC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/nextcure-inc-loss-submission-form?prid=9604&wire=1
Lead Plaintiff Deadline: November 20, 2020
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
GoHealth, Inc. (NASDAQ: GOCO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/gohealth-inc-loss-submission-form?prid=9604&wire=1
Lead Plaintiff Deadline: November 20, 2020
The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.
Allegations against GOCO include that: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.
Fluidigm Corporation (NASDAQ: FLDM)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fluidigm-corporation-loss-submission-form?prid=9604&wire=1
Lead Plaintiff Deadline: November 20, 2020
Class Period: February 7, 2019 - November 5, 2019
Allegations against FLDM include that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong